摘要
公共学术研究网站、私人机构以及小企业对降糖钒化合物的持续发展贡献。但为什么这一努力没有受到全球运营的也被称为“大制药公司”的制药公司的响应?有趣的是,今天的临床实践急需是改善或替代胰岛素治疗糖尿病(DM)。胰岛素是治疗和经济支柱。那么,为什么这些公司发展潜在的抗糖尿病药物的成分没有钒(无钒)?我们从专业文献收集了有关已知含钒抗糖尿病成分理化特性和药理特点信息,并转换数据成关于降糖钒的基础的解释(论点,“利弊”)。发现有些是按时间顺序排列的,而对过去十年的研究,关于钒的药用化学和它的历史也被列为进一步的了解。特别是,所谓的“非复杂或免费“钒物种的概念(即无机氧化协调物种)和“生物形态”降糖钒配合物被发现很关键,随后记录在更多的细节来回答问题。
关键词: 降糖药,类胰岛素,蛋白酪氨酸磷酸酶1B,钒配合物,形态,药物设计,分子建模。
Current Medicinal Chemistry
Title:Why Antidiabetic Vanadium Complexes are Not in the Pipeline of “Big Pharma” Drug Research? A Critical Review
Volume: 23 Issue: 25
Author(s): Thomas Scior, Jose Antonio Guevara-Garcia, Quoc-Tuan Do, Philippe Bernard, Stefan Laufer
Affiliation:
关键词: 降糖药,类胰岛素,蛋白酪氨酸磷酸酶1B,钒配合物,形态,药物设计,分子建模。
摘要: Public academic research sites, private institutions as well as small companies have made substantial contributions to the ongoing development of antidiabetic vanadium compounds. But why is this endeavor not echoed by the globally operating pharmaceutical companies, also known as “Big Pharma”? Intriguingly, today’s clinical practice is in great need to improve or replace insulin treatment against Diabetes Mellitus (DM). Insulin is the mainstay therapeutically and economically. So, why do those companies develop potential antidiabetic drug candidates without vanadium (vanadium- free)? We gathered information about physicochemical and pharmacological properties of known vanadium-containing antidiabetic compounds from the specialized literature, and converted the data into explanations (arguments, the “pros and cons”) about the underpinnings of antidiabetic vanadium. Some discoveries were embedded in chronological order while seminal reviews of the last decade about the Medicinal chemistry of vanadium and its history were also listed for further understanding. In particular, the concepts of so-called “noncomplexed or free” vanadium species (i.e. inorganic oxido-coordinated species) and “biogenic speciation” of antidiabetic vanadium complexes were found critical and subsequently documented in more details to answer the question.
Export Options
About this article
Cite this article as:
Thomas Scior, Jose Antonio Guevara-Garcia, Quoc-Tuan Do, Philippe Bernard, Stefan Laufer , Why Antidiabetic Vanadium Complexes are Not in the Pipeline of “Big Pharma” Drug Research? A Critical Review, Current Medicinal Chemistry 2016; 23 (25) . https://dx.doi.org/10.2174/0929867323666160321121138
DOI https://dx.doi.org/10.2174/0929867323666160321121138 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
2’-Deoxyribose Mediated Glycation Leads to Alterations in BSA Structure Via Generation of Carbonyl Species
Current Protein & Peptide Science Glycation and HMG-CoA Reductase Inhibitors: Implication in Diabetes and Associated Complications
Current Diabetes Reviews Soluble RAGE-Modulating Drugs: State-of-the-Art and Future Perspectives for Targeting Vascular Inflammation
Current Vascular Pharmacology Cardiovascular Disease among Patients with Diabetes: The Current Scenario in Saudi Arabia
Current Diabetes Reviews Pathophysiological Mechanisms Linking Type 2 Diabetes and Dementia: Review of Evidence from Clinical, Translational and Epidemiological Research
Current Diabetes Reviews The Potential Role of Angiotensin Converting Enzyme and Vasopeptidase Inhibitors in the Treatment of Diabetic Neuropathy
Current Drug Targets Flavonoids in the Treatment of Diabetes: Clinical Outcomes and Mechanism to Ameliorate Blood Glucose Levels
Current Diabetes Reviews Genomic and Pharmacogenomic Biomarkers of Parkinson’s Disease
Current Drug Metabolism Arterial Hypertension and Kidney Circulation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Patent Selections
Recent Patents on Cardiovascular Drug Discovery Dual Acting Anti-Inflammatory Drugs
Current Topics in Medicinal Chemistry Under the Microscope: Focus on Chlamydia pneumoniae Infection and Multiple Sclerosis
Current Neurovascular Research Prediction of Degeneration of Native and Bioprosthetic Aortic Valves:Issue-Related Particularities of Diabetes Mellitus
Infectious Disorders - Drug Targets Synthetic and Medicinal Prospective of Structurally Modified Curcumins
Current Topics in Medicinal Chemistry Neuron Protection as a Therapeutic Target in Acute Ischemic Stroke
Current Topics in Medicinal Chemistry Organoselenium Compounds as Potential Neuroprotective Therapeutic Agents
Current Organic Chemistry Pharmacological Approaches to Chronic Spinal Cord Injury
Current Pharmaceutical Design The Role of Chemokines, Cytokines and Adhesion Molecules in Stem Cell Trafficking and Homing
Current Pharmaceutical Design Current Advances on Different Kinases Involved in Tau Phosphorylation, and Implications in Alzheimers Disease and Tauopathies
Current Alzheimer Research Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry